Esophageal adenocarcinoma · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin, Irinotecan, RT Variant #01 | — | R 3 591 | 35d | — | — | ~1 | ~R 3 591 indirect | — |
Cisplatin and Paclitaxel (TP) and RT Variant #01 | — | R 2 425 | 21d | — | — | ~1 | ~R 2 425 PFS proxy · indirect | 1 |
Fluorouracil, Paclitaxel, RT Variant #01 | — | R 2 139 | 35d | — | — | ~1 | ~R 2 139 indirect | — |
Cisplatin and Fluorouracil (CF) and RT Variant #01 | — | R 1 774 | 17d | — | 16.0 mo | 1 | R 1 774 PFS proxy | — |
Cisplatin, Etoposide, RT Partial | — | — | — | — | — | — | — | — |
5 of 5 regimens shown